Pancreatic Ductal Adenocarcinoma (PDAC) trials recruiting in New York

All Pancreatic Ductal Adenocarcinoma (PDAC) trials nationally

Cities in New York

Recruiting trials in New York

• A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
  NCT07644559 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
  NCT07227168 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
  NCT07562152 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
  NCT07491445 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
  NCT07349537 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
  NCT05379985 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York
• Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
  NCT06040541 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · New York: New York